25 XP   0   0   10

Pharmaxis Ltd
Buy, Hold or Sell?

Let's analyse Pharmaxis together

PenkeI guess you are interested in Pharmaxis Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharmaxis Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharmaxis Ltd

I send you an email if I find something interesting about Pharmaxis Ltd.

Quick analysis of Pharmaxis (30 sec.)










What can you expect buying and holding a share of Pharmaxis? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.01
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.01
Return On Investment
-32.8%

For what price can you sell your share?

Current Price per Share
A$0.02
Expected price per share
A$0.016 - A$0.027
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Pharmaxis (5 min.)




Live pricePrice per Share (EOD)

A$0.02

Intrinsic Value Per Share

A$-0.27 - A$0.10

Total Value Per Share

A$-0.25 - A$0.12

2. Growth of Pharmaxis (5 min.)




Is Pharmaxis growing?

Current yearPrevious yearGrowGrow %
How rich?$6.2m$7m-$814.2k-13.0%

How much money is Pharmaxis making?

Current yearPrevious yearGrowGrow %
Making money-$7.4m-$1.2m-$6.1m-83.0%
Net Profit Margin-197.1%-26.1%--

How much money comes from the company's main activities?

3. Financial Health of Pharmaxis (5 min.)




3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Pharmaxis? (5 min.)

Welcome investor! Pharmaxis's management wants to use your money to grow the business. In return you get a share of Pharmaxis.

What can you expect buying and holding a share of Pharmaxis?

First you should know what it really means to hold a share of Pharmaxis. And how you can make/lose money.

Speculation

The Price per Share of Pharmaxis is A$0.021. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharmaxis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharmaxis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharmaxis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-49.0%-0.01-49.0%0.00-8.3%-0.01-43.3%-0.01-48.3%
Usd Book Value Change Per Share0.00-5.4%0.00-5.4%0.0134.3%0.00-1.3%-0.01-25.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-5.4%0.00-5.4%0.0134.3%0.00-1.3%-0.01-25.1%
Usd Price Per Share0.03-0.03-0.04-0.07-0.11-
Price to Earnings Ratio-3.12--3.12--24.34--12.34--4.02-
Price-to-Total Gains Ratio-28.44--28.44-5.90-13.85-8.41-
Price to Book Ratio3.70-3.70-4.35-15.28-16.37-
Price-to-Total Gains Ratio-28.44--28.44-5.90-13.85-8.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.013734
Number of shares72811
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (72811 shares)-82.04-20.55
Gains per Year (72811 shares)-328.17-82.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-328-3380-82-92
20-656-6660-164-174
30-985-9940-247-256
40-1313-13220-329-338
50-1641-16500-411-420
60-1969-19780-493-502
70-2297-23060-575-584
80-2625-26340-657-666
90-2954-29620-740-748
100-3282-32900-822-830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.08.00.020.0%2.018.02.09.1%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%12.010.00.054.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.022.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%12.010.00.054.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Pharmaxis

About Pharmaxis Ltd

Syntara Limited operates as a clinical stage drug development company that focuses on blood-related cancers. Its lead product candidate is PXS-5505, which is in phase 2 trial for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue leading to loss of red and white blood cells and platelets. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Fundamental data was last updated by Penke on 2024-02-03 22:46:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Pharmaxis Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharmaxis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -197.1% means that $-1.97 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharmaxis Ltd:

  • The MRQ is -197.1%. The company is making a huge loss. -2
  • The TTM is -197.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-197.1%TTM-197.1%0.0%
TTM-197.1%YOY-26.1%-171.0%
TTM-197.1%5Y-164.7%-32.3%
5Y-164.7%10Y-198.5%+33.8%
1.1.2. Return on Assets

Shows how efficient Pharmaxis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • -47.3% Return on Assets means that Pharmaxis generated $-0.47 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharmaxis Ltd:

  • The MRQ is -47.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -47.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-47.3%TTM-47.3%0.0%
TTM-47.3%YOY-7.7%-39.6%
TTM-47.3%5Y-28.3%-18.9%
5Y-28.3%10Y-25.0%-3.4%
1.1.3. Return on Equity

Shows how efficient Pharmaxis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • -118.8% Return on Equity means Pharmaxis generated $-1.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharmaxis Ltd:

  • The MRQ is -118.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -118.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-118.8%TTM-118.8%0.0%
TTM-118.8%YOY-17.9%-100.9%
TTM-118.8%5Y-270.5%+151.7%
5Y-270.5%10Y-213.0%-57.5%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Pharmaxis Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharmaxis is operating .

  • Measures how much profit Pharmaxis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -193.2% means the company generated $-1.93  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharmaxis Ltd:

  • The MRQ is -193.2%. The company is operating very inefficient. -2
  • The TTM is -193.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-193.2%TTM-193.2%0.0%
TTM-193.2%YOY-207.3%+14.1%
TTM-193.2%5Y-218.8%+25.6%
5Y-218.8%10Y-211.8%-7.0%
1.2.2. Operating Ratio

Measures how efficient Pharmaxis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 5.39 means that the operating costs are $5.39 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pharmaxis Ltd:

  • The MRQ is 5.386. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.386. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ5.386TTM5.3860.000
TTM5.386YOY5.406-0.020
TTM5.3865Y5.348+0.039
5Y5.34810Y4.990+0.357
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Pharmaxis Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharmaxis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.33 means the company has $2.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharmaxis Ltd:

  • The MRQ is 2.325. The company is able to pay all its short-term debts. +1
  • The TTM is 2.325. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.325TTM2.3250.000
TTM2.325YOY3.153-0.828
TTM2.3255Y3.456-1.130
5Y3.45610Y4.107-0.652
1.3.2. Quick Ratio

Measures if Pharmaxis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.42 means the company can pay off $2.42 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharmaxis Ltd:

  • The MRQ is 2.424. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.424. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.424TTM2.4240.000
TTM2.424YOY3.701-1.277
TTM2.4245Y4.596-2.172
5Y4.59610Y5.032-0.436
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Pharmaxis Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharmaxis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharmaxis to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.60 means that Pharmaxis assets are financed with 60.2% credit (debt) and the remaining percentage (100% - 60.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharmaxis Ltd:

  • The MRQ is 0.602. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.602. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.602TTM0.6020.000
TTM0.602YOY0.571+0.031
TTM0.6025Y0.753-0.151
5Y0.75310Y0.744+0.010
1.4.2. Debt to Equity Ratio

Measures if Pharmaxis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 151.3% means that company has $1.51 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharmaxis Ltd:

  • The MRQ is 1.513. The company is just able to pay all its debts with equity.
  • The TTM is 1.513. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.513TTM1.5130.000
TTM1.513YOY1.331+0.182
TTM1.5135Y7.991-6.478
5Y7.99110Y6.147+1.844
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Pharmaxis Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pharmaxis generates.

  • Above 15 is considered overpriced but always compare Pharmaxis to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -3.12 means the investor is paying $-3.12 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharmaxis Ltd:

  • The EOD is -1.336. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.117. Based on the earnings, the company is expensive. -2
  • The TTM is -3.117. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.336MRQ-3.117+1.781
MRQ-3.117TTM-3.1170.000
TTM-3.117YOY-24.337+21.220
TTM-3.1175Y-12.343+9.226
5Y-12.34310Y-4.022-8.321
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharmaxis Ltd:

  • The EOD is -2.047. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.775. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.775. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.047MRQ-4.775+2.729
MRQ-4.775TTM-4.7750.000
TTM-4.775YOY-2.828-1.947
TTM-4.7755Y-34.472+29.697
5Y-34.47210Y-17.194-17.278
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharmaxis is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Pharmaxis Ltd:

  • The EOD is 1.587. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.704. Based on the equity, the company is fair priced.
  • The TTM is 3.704. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.587MRQ3.704-2.117
MRQ3.704TTM3.7040.000
TTM3.704YOY4.347-0.643
TTM3.7045Y15.285-11.581
5Y15.28510Y16.370-1.085
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Pharmaxis Ltd.

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Pharmaxis Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.0020%0.011-116%0.000-75%-0.008+369%
Book Value Per Share--0.0130.0130%0.015-12%0.011+21%0.018-26%
Current Ratio--2.3252.3250%3.153-26%3.456-33%4.107-43%
Debt To Asset Ratio--0.6020.6020%0.571+5%0.753-20%0.744-19%
Debt To Equity Ratio--1.5131.5130%1.331+14%7.991-81%6.147-75%
Dividend Per Share----0%-0%-0%-0%
Eps---0.016-0.0160%-0.003-83%-0.014-12%-0.015-1%
Free Cash Flow Per Share---0.010-0.0100%-0.023+124%-0.010-2%-0.009-17%
Free Cash Flow To Equity Per Share---0.001-0.0010%-0.014+2188%-0.001+37%-0.005+733%
Gross Profit Margin--1.0271.0270%1.390-26%1.213-15%1.109-7%
Intrinsic Value_10Y_max--0.104--------
Intrinsic Value_10Y_min---0.266--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.014--------
Intrinsic Value_3Y_max---0.002--------
Intrinsic Value_3Y_min---0.054--------
Intrinsic Value_5Y_max--0.014--------
Intrinsic Value_5Y_min---0.105--------
Market Cap15174894.336-133%35408086.78435408086.7840%46969911.040-25%75729948.877-53%117424777.600-70%
Net Profit Margin---1.971-1.9710%-0.261-87%-1.647-16%-1.985+1%
Operating Margin---1.932-1.9320%-2.073+7%-2.188+13%-2.118+10%
Operating Ratio--5.3865.3860%5.4060%5.348+1%4.990+8%
Pb Ratio1.587-133%3.7043.7040%4.347-15%15.285-76%16.370-77%
Pe Ratio-1.336+57%-3.117-3.1170%-24.337+681%-12.343+296%-4.022+29%
Price Per Share0.021-133%0.0490.0490%0.065-25%0.105-53%0.163-70%
Price To Free Cash Flow Ratio-2.047+57%-4.775-4.7750%-2.828-41%-34.472+622%-17.194+260%
Price To Total Gains Ratio-12.189+57%-28.440-28.4400%5.901-582%13.847-305%8.413-438%
Quick Ratio--2.4242.4240%3.701-35%4.596-47%5.032-52%
Return On Assets---0.473-0.4730%-0.077-84%-0.283-40%-0.250-47%
Return On Equity---1.188-1.1880%-0.179-85%-2.705+128%-2.130+79%
Total Gains Per Share---0.002-0.0020%0.011-116%0.000-75%-0.008+369%
Usd Book Value--6251586.0006251586.0000%7065816.000-12%5160452.400+21%8463152.400-26%
Usd Book Value Change Per Share---0.001-0.0010%0.007-116%0.000-75%-0.005+369%
Usd Book Value Per Share--0.0090.0090%0.010-12%0.007+21%0.012-26%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.010-0.0100%-0.002-83%-0.009-12%-0.010-1%
Usd Free Cash Flow---4849410.000-4849410.0000%-10862940.000+124%-4766221.200-2%-4018241.400-17%
Usd Free Cash Flow Per Share---0.007-0.0070%-0.015+124%-0.007-2%-0.006-17%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.009+2188%-0.001+37%-0.003+733%
Usd Market Cap9924380.896-133%23156888.75723156888.7570%30718321.820-25%49527386.565-53%76795804.550-70%
Usd Price Per Share0.014-133%0.0320.0320%0.043-25%0.069-53%0.106-70%
Usd Profit---7429440.000-7429440.0000%-1266144.000-83%-6606054.000-11%-7340365.200-1%
Usd Revenue--3770310.0003770310.0000%4856604.000-22%4260679.200-12%8518611.600-56%
Usd Total Gains Per Share---0.001-0.0010%0.007-116%0.000-75%-0.005+369%
 EOD+3 -5MRQTTM+0 -0YOY+10 -245Y+11 -2310Y+13 -21

4.2. Fundamental Score

Let's check the fundamental score of Pharmaxis Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.336
Price to Book Ratio (EOD)Between0-11.587
Net Profit Margin (MRQ)Greater than0-1.971
Operating Margin (MRQ)Greater than0-1.932
Quick Ratio (MRQ)Greater than12.424
Current Ratio (MRQ)Greater than12.325
Debt to Asset Ratio (MRQ)Less than10.602
Debt to Equity Ratio (MRQ)Less than11.513
Return on Equity (MRQ)Greater than0.15-1.188
Return on Assets (MRQ)Greater than0.05-0.473
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Pharmaxis Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.359
Ma 20Greater thanMa 500.019
Ma 50Greater thanMa 1000.022
Ma 100Greater thanMa 2000.028
OpenGreater thanClose0.021
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets24,026
Total Liabilities14,467
Total Stockholder Equity9,559
 As reported
Total Liabilities 14,467
Total Stockholder Equity+ 9,559
Total Assets = 24,026

Assets

Total Assets24,026
Total Current Assets18,678
Long-term Assets5,348
Total Current Assets
Cash And Cash Equivalents 9,230
Short-term Investments 2,768
Net Receivables 7,476
Other Current Assets 331
Total Current Assets  (as reported)18,678
Total Current Assets  (calculated)19,805
+/- 1,127
Long-term Assets
Property Plant Equipment 1,843
Intangible Assets 682
Other Assets 2,823
Long-term Assets  (as reported)5,348
Long-term Assets  (calculated)5,348
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,033
Long-term Liabilities6,434
Total Stockholder Equity9,559
Total Current Liabilities
Short-term Debt 2,043
Accounts payable 1,582
Other Current Liabilities 3,469
Total Current Liabilities  (as reported)8,033
Total Current Liabilities  (calculated)7,094
+/- 939
Long-term Liabilities
Other Liabilities 6,434
Long-term Liabilities  (as reported)6,434
Long-term Liabilities  (calculated)6,434
+/-0
Total Stockholder Equity
Common Stock389,699
Retained Earnings -404,453
Other Stockholders Equity 24,313
Total Stockholder Equity (as reported)9,559
Total Stockholder Equity (calculated)9,559
+/-0
Other
Capital Stock389,699
Cash And Equivalents5,978
Cash and Short Term Investments 9,230
Common Stock Shares Outstanding 655,624
Current Deferred Revenue939
Liabilities and Stockholders Equity 24,026
Net Debt -7,187
Net Invested Capital 9,559
Net Tangible Assets 8,877
Net Working Capital 10,645
Property Plant and Equipment Gross 43,264
Short Long Term Debt Total 2,043



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-30
> Total Assets 
2,144
29,795
28,261
37,937
104,267
82,648
125,049
163,997
140,767
94,572
131,700
112,280
66,747
82,558
65,653
45,434
50,097
52,668
35,416
33,590
25,186
24,026
24,02625,18633,59035,41652,66850,09745,43465,65382,55866,747112,280131,70094,572140,767163,997125,04982,648104,26737,93728,26129,7952,144
   > Total Current Assets 
0
26,831
25,365
34,092
99,311
77,287
118,589
126,466
88,922
46,003
87,274
71,937
40,895
61,540
46,417
28,643
35,984
40,575
24,492
25,309
19,232
18,678
18,67819,23225,30924,49240,57535,98428,64346,41761,54040,89571,93787,27446,00388,922126,466118,58977,28799,31134,09225,36526,8310
       Cash And Cash Equivalents 
751
26,684
25,217
935
97,840
76,182
111,842
124,993
85,787
44,343
81,475
63,943
34,182
54,138
39,209
21,504
31,073
31,124
14,764
18,712
8,937
9,230
9,2308,93718,71214,76431,12431,07321,50439,20954,13834,18263,94381,47544,34385,787124,993111,84276,18297,84093525,21726,684751
       Short-term Investments 
0
0
24,099
32,455
0
0
0
0
0
0
0
0
0
0
35,182
16,479
255
28,333
11,312
8,528
5,996
2,768
2,7685,9968,52811,31228,33325516,47935,182000000000032,45524,09900
       Net Receivables 
0
63
0
106
590
640
2,410
700
2,380
683
4,252
5,770
4,518
5,735
4,849
4,435
2,394
7,191
6,936
2,736
7,642
7,476
7,4767,6422,7366,9367,1912,3944,4354,8495,7354,5185,7704,2526832,3807002,4106405901060630
       Inventory 
0
0
0
0
100
79
96
254
424
864
1,477
2,171
2,150
1,575
2,213
2,570
2,398
2,116
2,630
3,638
2,337
1,641
1,6412,3373,6382,6302,1162,3982,5702,2131,5752,1502,1711,47786442425496791000000
   > Long-term Assets 
0
2,964
2,896
3,846
4,956
5,361
6,460
37,531
51,845
48,569
44,426
40,343
25,852
21,018
19,236
16,791
14,113
12,093
10,924
8,281
5,954
5,348
5,3485,9548,28110,92412,09314,11316,79119,23621,01825,85240,34344,42648,56951,84537,5316,4605,3614,9563,8462,8962,9640
       Property Plant Equipment 
116
1,515
1,474
2,477
3,205
3,521
3,668
32,698
32,537
30,570
27,683
25,115
22,448
19,634
17,793
14,860
12,451
10,264
8,906
6,226
3,212
1,843
1,8433,2126,2268,90610,26412,45114,86017,79319,63422,44825,11527,68330,57032,53732,6983,6683,5213,2052,4771,4741,515116
       Long Term Investments 
0
0
0
0
0
0
1,361
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,361000000
       Intangible Assets 
1,208
1,205
1,162
1,106
1,195
1,239
1,227
1,193
17,702
15,954
14,143
12,429
1,258
363
146
503
446
755
941
1,113
1,024
682
6821,0241,1139417554465031463631,25812,42914,14315,95417,7021,1931,2271,2391,1951,1061,1621,2051,208
       Other Assets 
0
244
260
262
556
601
1,526
3,392
1,606
2,045
2,600
2,799
2,146
1,021
1,297
1,428
1,216
1,074
1,077
942
2,562
2,823
2,8232,5629421,0771,0741,2161,4281,2971,0212,1462,7992,6002,0451,6063,3921,5266015562622602440
> Total Liabilities 
190
604
1,481
2,369
5,379
6,089
5,928
26,306
25,751
23,742
21,897
44,385
48,680
46,237
44,727
41,913
38,979
37,854
33,985
30,745
14,382
14,467
14,46714,38230,74533,98537,85438,97941,91344,72746,23748,68044,38521,89723,74225,75126,3065,9286,0895,3792,3691,481604190
   > Total Current Liabilities 
190
603
1,471
2,342
5,310
5,974
5,740
9,197
9,169
7,743
6,779
8,613
8,282
8,148
11,012
10,521
8,244
8,112
6,825
7,887
6,099
8,033
8,0336,0997,8876,8258,1128,24410,52111,0128,1488,2828,6136,7797,7439,1699,1975,7405,9745,3102,3421,471603190
       Short-term Debt 
0
0
0
32,455
0
0
0
316
371
443
515
594
679
772
864
981
1,098
1,203
1,832
2,032
2,031
2,043
2,0432,0312,0321,8321,2031,09898186477267959451544337131600032,455000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
11,572
10,893
10,122
9,251
8,269
0
0
0
0
0
000008,2699,25110,12210,89311,572000000000000
       Accounts payable 
121
232
245
757
813
2,654
516
1,582
1,086
1,235
922
1,145
1,776
2,700
2,196
3,324
2,130
2,197
1,760
1,240
615
1,582
1,5826151,2401,7602,1972,1303,3242,1962,7001,7761,1459221,2351,0861,5825162,654813757245232121
       Other Current Liabilities 
69
371
1,226
1,585
4,497
3,320
5,224
7,299
7,712
6,065
5,342
6,874
5,827
4,676
7,952
6,216
5,016
1,107
478
1,018
259
3,469
3,4692591,0184781,1075,0166,2167,9524,6765,8276,8745,3426,0657,7127,2995,2243,3204,4971,5851,22637169
   > Long-term Liabilities 
0
1
10
26
69
115
188
17,109
16,582
15,999
15,118
35,772
40,398
38,089
33,715
31,392
30,735
29,742
27,160
22,858
8,283
6,434
6,4348,28322,85827,16029,74230,73531,39233,71538,08940,39835,77215,11815,99916,58217,10918811569261010
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,258
8,270
7,171
5,968
6,322
4,290
2,259
0
02,2594,2906,3225,9687,1718,2709,25800000000000000
       Other Liabilities 
0
1
10
0
0
115
188
3,550
3,424
3,283
2,973
24,212
29,505
27,968
24,457
23,122
23,564
23,774
20,838
18,568
8,631
6,434
6,4348,63118,56820,83823,77423,56423,12224,45727,96829,50524,2122,9733,2833,4243,550188115001010
> Total Stockholder Equity
1,953
29,190
26,780
35,569
98,888
76,559
119,121
137,691
115,016
70,830
109,803
67,895
18,067
36,321
20,926
3,521
11,118
14,814
1,431
2,845
10,804
9,559
9,55910,8042,8451,43114,81411,1183,52120,92636,32118,06767,895109,80370,830115,016137,691119,12176,55998,88835,56926,78029,1901,953
   Common Stock
1,400
32,105
35,695
54,716
134,745
135,108
194,680
245,958
267,050
267,610
344,388
344,623
344,623
344,623
344,623
344,623
344,623
367,301
367,301
371,366
380,440
389,699
389,699380,440371,366367,301367,301344,623344,623344,623344,623344,623344,623344,388267,610267,050245,958194,680135,108134,74554,71635,69532,1051,400
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
0
-250
-651
-1,187
2,522
4,009
7,439
9,902
12,480
13,492
14,331
15,725
17,715
17,503
18,571
19,512
20,681
21,757
22,317
22,636
23,457
24,313
24,31323,45722,63622,31721,75720,68119,51218,57117,50317,71515,72514,33113,49212,4809,9027,4394,0092,522-1,187-651-2500
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1
0
7,153
0
0
0
0
0
17,715
-153
18,571
19,512
20,681
21,757
22,317
22,636
23,457
24,313
24,31323,45722,63622,31721,75720,68119,51218,571-15317,715000007,153010000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.